Navigation Links
China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
Date:11/20/2008

BEIJING, Nov. 20 /PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it has successfully completed the development of two proprietary molecular diagnostic kits for the detection of epidermal growth factor receptor ("EGFR") abnormalities in patients with non-small cell lung cancer ("NSCLC"). The Company expects to offer the kits to its hospital customers through its direct sales force in January 2009.

Currently, Iressa and Tarceva are commonly used drugs for the treatment of patients with NSCLC. These drugs target the EGFR gene located at 7p12. According to publications in medical journals, EGFR abnormalities have been found in approximately 85% of NSCLC patients responsive to Iressa and Tarceva. Some of these abnormalities could be identified by using FISH-based technique to detect increase in gene copy numbers; others could be detected by using real-time PCR-based technique to analyze EGFR gene mutations. The Company has successfully completed the development of both FISH and real-time PCR-based molecular diagnostic kits for detecting EGFR abnormalities. The test result provides guidance for physicians to determine the most appropriate therapy for patients with NSCLC.

"We are excited about the successful development of molecular diagnostic kits for non-small cell lung cancer therapy," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "We will continue to leverage our molecular diagnostic technology platforms to develop more products with significant market potential."

Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer death in China. It is estimated that more than 500,000 new lung cancer cases were diagnosed each year in China and the incidence rate of lung cancer is expected to continue to increase.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833
     Email: IR@chinameditech.com

'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
4. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
5. China Biologic Products Announces Third Quarter 2008 Results Conference Call
6. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
7. China Clean Energy Resumes Biodiesel Production After Temporary Halt
8. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb.10, 2016 ASAE is introducing a hybrid ... Companies (AMC) the option of joining or renewing through ... determined by staff size, every employee in any size ... and reap all available member benefits.   ... organizational membership options will allow organizations of any size ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused ... announced today it has been selected to present at the Cavendish Global Health Impact ... Florida. The purpose of the Forum is to help family offices and foundations ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
Breaking Biology News(10 mins):